Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review.
clozapine
drowsiness
maintenance of wakefulness test (MWT)
multiple sleep latency test (MSLT)
polysomnography (PSG)
sleepiness
Journal
Journal of sleep research
ISSN: 1365-2869
Titre abrégé: J Sleep Res
Pays: England
ID NLM: 9214441
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
revised:
30
08
2024
received:
19
06
2024
accepted:
09
09
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
aheadofprint
Résumé
Clozapine is effective in treatment-resistant schizophrenia but with adverse effects including sedation. Excessive daytime sleepiness, a symptom of hypersomnolence, is the most frequently reported subjective side-effect. The aim of this systematic review was to synthesise the literature evaluating the impact of clozapine on the objective assessment of hypersomnolence in people with schizophrenia. We systematically searched databases for articles evaluating hypersomnolence with electrophysiological or psychomotor/cognitive measures in clozapine-treated patients with schizophrenia. Objective assessment of hypersomnolence was evaluated in six studies. All studies using polysomnography (PSG) found significantly longer total sleep time and shorter sleep onset latency in patients treated with clozapine at initiation of clozapine. The study with the multiple sleep latency test (MSLT) also found a shorter sleep onset latency. These observations did not persist 4-6 weeks after treatment initiation. Further investigations are needed. Longer total sleep time should be investigated with standardised long-term PSG to investigate excessive sleep quantity. Shorter sleep onset latency should be investigated with the MSLT or the maintenance of wakefulness test to investigate the excessive propensity to fall asleep or ability to stay awake. Lastly, sleep inertia should be investigated specifically in the morning.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14360Subventions
Organisme : INSERM, Bordeaux Population Health Research Center
Organisme : UMR 1219
Organisme : UMR CNRS 6033 SANPSY
Organisme : University Hospital of Bordeaux
Informations de copyright
© 2024 European Sleep Research Society.
Références
Åkerstedt, T., Bellocco, R., Widman, L., Eriksson, J., Ye, W., Adami, H.‐O., & Trolle Lagerros, Y. (2024). The association of short and long sleep with mortality in men and women. Journal of Sleep Research, 33(2), e13931. https://doi.org/10.1111/jsr.13931
Åkerstedt, T., Ghilotti, F., Grotta, A., Bellavia, A., Lagerros, Y. T., & Bellocco, R. (2017). Sleep duration, mortality and the influence of age. European Journal of Epidemiology, 32(10), 881–891.
Åkerstedt, T., Ghilotti, F., Grotta, A., Zhao, H., Adami, H.‐O., Trolle‐Lagerros, Y., & Bellocco, R. (2019). Sleep duration and mortality—Does weekend sleep matter? Journal of Sleep Research, 28(1), e12712.
Alphs, L. D., & Anand, R. (1999). Clozapine: The commitment to patient safety. The Journal of Clinical Psychiatry, 60(Suppl 12), 39–42.
American Academy of Sleep Medicine. (2014). International classification of sleep disorders‐third edition (ICSD‐3).
Angermeyer, M. C., Löffler, W., Müller, P., Schulze, B., & Priebe, S. (2001). Patients' and relatives' assessment of clozapine treatment. Psychological Medicine, 31(3), 509–517.
Arand, D., Bonnet, M., Hurwitz, T., Mitler, M., Rosa, R., & Sangal, R. B. (2005). The clinical use of the MSLT and MWT. Sleep, 28(1), 123–144.
Armitage, R., Cole, D., Suppes, T., & Ozcan, M. E. (2004). Effects of clozapine on sleep in bipolar and schizoaffective disorders. Progress in Neuro‐Psychopharmacology & Biological Psychiatry, 28(7), 1065–1070.
Arranz, B., Garriga, M., García‐Rizo, C., & San, L. (2018). Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 28(2), 227–242.
Baiardi, S., & Mondini, S. (2020). Inside the clinical evaluation of sleepiness: Subjective and objective tools. Sleep & Breathing = Schlaf & Atmung, 24(1), 369–377.
Barnes, C. M., & Watson, N. F. (2019). Why healthy sleep is good for business. Sleep Medicine Reviews, 47, 112–118.
Bennett, L. S., Stradling, J. R., & Davies, R. J. (1997). A behavioural test to assess daytime sleepiness in obstructive sleep apnoea. Journal of Sleep Research, 6(2), 142–145.
Bioulac, S., Micoulaud‐Franchi, J.‐A., Arnaud, M., Sagaspe, P., Moore, N., Salvo, F., & Philip, P. (2017). Risk of motor vehicle accidents related to sleepiness at the wheel: A systematic review and meta‐analysis. Sleep, 40(10), zsx134. https://doi.org/10.1093/sleep/zsx134
Byun, J.‐H., Kim, K. T., Moon, H.‐J., Motamedi, G. K., & Cho, Y. W. (2019). The first night effect during polysomnography, and patients' estimates of sleep quality. Psychiatry Research, 274, 27–29.
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., De Luca, V., Iasevoli, F., & Correll, C. U. (2022). Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment‐resistant schizophrenia. Pharmacology & Therapeutics, 236, 108236. https://doi.org/10.1016/j.pharmthera.2022.108236
Dinges, D. F., & Powell, J. W. (1985). Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behavior Research Methods, Instruments, & Computers, 17(6), 652–655.
Doghramji, K., Mitler, M. M., Sangal, R. B., Shapiro, C., Taylor, S., Walsleben, J., Belisle, C., Erman, M. K., Hayduk, R., Hosn, R., O'Malley, E. B., Sangal, J. M., Schutte, S. L., & Youakim, J. M. (1997). A normative study of the maintenance of wakefulness test (MWT). Electroencephalography and Clinical Neurophysiology, 103(5), 554–562.
Evangelista, E., Lopez, R., Barateau, L., Chenini, S., Bosco, A., Jaussent, I., & Dauvilliers, Y. (2018). Alternative diagnostic criteria for idiopathic hypersomnia: A 32‐hour protocol. Annals of Neurology, 83(2), 235–247.
Evangelista, E., Rassu, A. L., Lopez, R., Biagioli, N., Chenini, S., Barateau, L., Jaussent, I., & Dauvilliers, Y. (2022). Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia. Sleep, 45(1), zsab220.
Frogley, C., Taylor, D., Dickens, G., & Picchioni, M. (2012). A systematic review of the evidence of clozapine's anti‐aggressive effects. The International Journal of Neuropsychopharmacology, 15(9), 1351–1371.
Gandhi, K. D., Mansukhani, M. P., Silber, M. H., & Kolla, B. P. (2021). Excessive daytime sleepiness: A clinical review. Mayo Clinic Proceedings, 96(5), 1288–1301.
Garbarino, S., Guglielmi, O., Sanna, A., Mancardi, G. L., & Magnavita, N. (2016). Risk of occupational accidents in workers with obstructive sleep apnea: Systematic review and meta‐analysis. Sleep, 39(6), 1211–1218.
Han, M., Zhang, X. Y., Chen, D. C., Tan, Y. L., Song, C. S., Yu, Y. H., & Huang, X. F. (2015). Cognitive differences in schizophrenia on long‐term treatments with clozapine, risperidone and typical antipsychotics. International Clinical Psychopharmacology, 30(2), 89–95.
Hennen, J., & Baldessarini, R. J. (2005). Suicidal risk during treatment with clozapine: A meta‐analysis. Schizophrenia Research, 73(2–3), 139–145.
Hinze‐Selch, D., Mullington, J., Orth, A., Lauer, C. J., & Pollmächer, T. (1997). Effects of clozapine on sleep: A longitudinal study. Biological Psychiatry, 42(4), 260–266.
Huhn, M., Nikolakopoulou, A., Schneider‐Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‐episode schizophrenia: A systematic review and network meta‐analysis. The Lancet, 394(10202), 939–951.
Jike, M., Itani, O., Watanabe, N., Buysse, D. J., & Kaneita, Y. (2018). Long sleep duration and health outcomes: A systematic review, meta‐analysis and meta‐regression. Sleep Medicine Reviews, 39, 25–36.
Kanady, J. C., & Harvey, A. G. (2015). Development and validation of the sleep inertia questionnaire (SIQ) and assessment of sleep inertia in analogue and clinical depression. Cognitive Therapy and Research, 39(5), 601–612. https://doi.org/10.1007/s10608-015-9686-4
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796.
Kaneda, Y., Jayathilak, K., & Meltzer, H. (2010). Determinants of work outcome in neuroleptic‐resistant schizophrenia and schizoaffective disorder: Cognitive impairment and clozapine treatment. Psychiatry Research, 178(1), 57–62.
Kaplan, K. A., Plante, D. T., Cook, J. D., & Harvey, A. G. (2019). Development and validation of the hypersomnia severity index (HSI): A measure to assess hypersomnia severity and impairment in psychiatric disorders. Psychiatry Research, 281, 112547.
Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018). Unique effects of clozapine: A pharmacological perspective. Advances in Pharmacology, 82, 137–162.
Kluge, M., Himmerich, H., Wehmeier, P. M., Rummel‐Kluge, C., Dalal, M., Hinze‐Selch, D., Kraus, T., Dittmann, R. W., Pollmächer, T., & Schuld, A. (2012). Sleep propensity at daytime as assessed by multiple sleep latency tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine. Schizophrenia Research, 135(1–3), 123–127.
Kluge, M., Schacht, A., Himmerich, H., Rummel‐Kluge, C., Wehmeier, P. M., Dalal, M., Hinze‐Selch, D., Kraus, T., Dittmann, R. W., Pollmächer, T., & Schuld, A. (2014). Olanzapine and clozapine differently affect sleep in patients with schizophrenia: Results from a double‐blind, polysomnographic study and review of the literature. Schizophrenia Research, 152(1), 255–260.
Lee, J. H., Woo, J. I., & Meltzer, H. Y. (2001). Effects of clozapine on sleep measures and sleep‐associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry Research, 103(2–3), 157–166.
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple‐treatments meta‐analysis. The Lancet, 382(9896), 951–962.
Lindberg, E., Carter, N., Gislason, T., & Janson, C. (2001). Role of snoring and daytime sleepiness in occupational accidents. American Journal of Respiratory and Critical Care Medicine, 164(11), 2031–2035.
Littner, M. R., Kushida, C., Wise, M., Davila, D. G., Morgenthaler, T., Lee‐Chiong, T., Hirshkowitz, M., Daniel, L. L., Bailey, D., Berry, R. B., Kapen, S., Kramer, M., & Standards of Practice Committee of the American Academy of Sleep Medicine. (2005). Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep, 28(1), 113–121.
Martin, V. P., Lopez, R., Dauvilliers, Y., Rouas, J.‐L., Philip, P., & Micoulaud‐Franchi, J.‐A. (2023). Sleepiness in adults: An umbrella review of a complex construct. Sleep Medicine Reviews, 67, 101718.
Mentzel, T. Q., van der Snoek, R., Lieverse, R., Oorschot, M., Viechtbauer, W., Bloemen, O., & van Harten, P. N. (2018). Clozapine monotherapy as a treatment for antipsychotic‐induced tardive dyskinesia: A meta‐analysis. The Journal of Clinical Psychiatry, 79(6), 17r11852.
Mitler, M. M., Gujavarty, K. S., & Browman, C. P. (1982). Maintenance of wakefulness test: A polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroencephalography and Clinical Neurophysiology, 53(6), 658–661.
Myles, N., Myles, H., Xia, S., Large, M., Kisely, S., Galletly, C., Bird, R., & Siskind, D. (2018). Meta‐analysis examining the epidemiology of clozapine‐associated neutropenia. Acta Psychiatrica Scandinavica, 138(2), 101–109.
Nielsen, J., Young, C., Ifteni, P., Kishimoto, T., Xiang, Y. T., Schulte, P. F. J., Correll, C. U., & Taylor, D. (2016). Worldwide differences in regulations of clozapine use. CNS Drugs, 30(2), 149–161.
Ohayon, M. M. (2008). From wakefulness to excessive sleepiness: What we know and still need to know. Sleep Medicine Reviews, 12(2), 129–141.
Ohayon, M. M., Dauvilliers, Y., & Reynolds, C. F. (2012). Operational definitions and algorithms for excessive sleepiness in the general population: Implications for DSM‐5 nosology. Archives of General Psychiatry, 69(1), 71–79.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo‐Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.
Peter‐Derex, L., Micoulaud‐Franchi, J.‐A., Lopez, R., & Barateau, L. (2023). Evaluation of hypersomnolence: From symptoms to diagnosis, a multidimensional approach. Revue Neurologique, 179(7), 715–726.
Peter‐Derex, L., Perrin, F., Petitjean, T., Garcia‐Larrea, L., & Bastuji, H. (2013). Discriminating neurological from psychiatric hypersomnia using the forced awakening test. Neurophysiologie Clinique = Clinical Neurophysiology, 43(3), 171–179.
Philip, P., Chaufton, C., Taillard, J., Sagaspe, P., Léger, D., Raimondi, M., Vakulin, A., & Capelli, A. (2013). Maintenance of wakefulness test scores and driving performance in sleep disorder patients and controls. International Journal of Psychophysiology, 89(2), 195–202.
Philip, P., & Sagaspe, P. (2011). Sommeil et accidents. Bulletin de l'Académie Nationale de Médecine, 195(7), 1635–1643.
Philip, P., Sagaspe, P., Lagarde, E., Leger, D., Ohayon, M. M., Bioulac, B., Boussuge, J., & Taillard, J. (2010). Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Medicine, 11(10), 973–979.
Philip, P., Sagaspe, P., Taillard, J., Chaumet, G., Bayon, V., Coste, O., Bioulac, B., & Guilleminault, C. (2008). Maintenance of wakefulness test, obstructive sleep apnea syndrome, and driving risk. Annals of Neurology, 64(4), 410–416.
Philip, P., Taillard, J., & Micoulaud‐Franchi, J.‐A. (2019). Sleep restriction, sleep hygiene, and driving safety: The importance of situational sleepiness. Sleep Medicine Clinics, 14(4), 407–412.
Pizza, F., Moghadam, K. K., Vandi, S., Detto, S., Poli, F., Mignot, E., Ferri, R., & Plazzi, G. (2013). Daytime continuous polysomnography predicts MSLT results in hypersomnias of central origin. Journal of Sleep Research, 22(1), 32–40.
Poceta, J. S., Timms, R. M., Jeong, D. U., Ho, S. L., Erman, M. K., & Mitler, M. M. (1992). Maintenance of wakefulness test in obstructive sleep apnea syndrome. Chest, 101(4), 893–897.
Quiles, C., & Verdoux, H. (2020). Clozapine. Encyclopédie Médico Chirurgicale Psychiatrie, 37‐860‐B‐30.
Robertson, I. H., Manly, T., Andrade, J., Baddeley, B. T., & Yiend, J. (1997). ‘Oops!’: Performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Neuropsychologia, 35(6), 747–758.
Safferman, A., Lieberman, J. A., Kane, J. M., Szymanski, S., & Kinon, B. (1991). Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17(2), 247–261.
Sateia, M. J. (2014). International classification of sleep disorders‐third edition: Highlights and modifications. Chest, 146(5), 1387–1394.
Thorpy, M. J. (1992). The clinical use of the multiple sleep latency test. The standards of practice Committee of the American Sleep Disorders Association. Sleep, 15(3), 268–276.
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009). 11‐year follow‐up of mortality in patients with schizophrenia: A population‐based cohort study (FIN11 study). The Lancet, 374(9690), 620–627.
van Schie, M. K. M., Lammers, G. J., Fronczek, R., Middelkoop, H. A. M., & van Dijk, J. G. (2021). Vigilance: Discussion of related concepts and proposal for a definition. Sleep Medicine, 83, 175–181.
Verdoux, H., Quiles, C., Cervello, S., Dubreucq, J., Bon, L., Massoubre, C., Pommier, R., Legros‐Lafarge, E., Jaafari, N., Guillard‐Bouhet, N., Chéreau‐Boudet, I., Couhet, G., Plasse, J., & Franck, N. (2019). Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: A REHABase cohort study. Psychiatry Research, 281, 112543.
Vernet, C., & Arnulf, I. (2009). Idiopathic hypersomnia with and without long sleep time: A controlled series of 75 patients. Sleep, 32(6), 753–759.
Wetter, T. C., Lauer, C. J., Gillich, G., & Pollmächer, T. (1996). The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. Journal of Psychiatric Research, 30(6), 411–419.
Wimberley, T., MacCabe, J. H., Laursen, T. M., Sørensen, H. J., Astrup, A., Horsdal, H. T., Gasse, C., & Støvring, H. (2017). Mortality and self‐harm in association with clozapine in treatment‐resistant schizophrenia. The American Journal of Psychiatry, 174(10), 990–998.
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005). A meta‐analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. The International Journal of Neuropsychopharmacology, 8(3), 457–472.